Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer

Abstract

Prostate cancer (PCa) is the second leading cause of cancer-related death in the US. Androgen receptor (AR) signaling is the driver of both PCa development and progression and, thus, the major target of current in-use therapies. However, despite the survival benefit of second-generation inhibitors of AR signaling in the metastatic setting, resistance mechanisms inevitably occur. Thus, novel strategies are required to circumvent resistance occurrence and thereby to improve PCa survival. Among the key cellular processes that are regulated by androgens, metabolic reprogramming stands out because of its intricate links with cancer cell biology. In this review, we discuss how cancer metabolism and lipid metabolism in particular are regulated by androgens and contribute to the acquisition of resistance to endocrine therapy. We describe the interplay between genetic alterations, metabolic vulnerabilities and castration resistance. Since PCa cells adapt their metabolism to excess nutrient supply to promote cancer progression, we review our current knowledge on the association between diet/obesity and resistance to anti-androgen therapies. We briefly describe the metabolic symbiosis between PCa cells and tumor microenvironment and how this crosstalk might contribute to PCa progression. We discuss how tackling PCa metabolic vulnerabilities represents a potential approach of synthetic lethality to endocrine therapies. Finally, we describe how the continuous advances in analytical technologies and metabolic imaging have led to the identification of potential new prognostic and predictive biomarkers, and non-invasive approaches to monitor therapy response.

Keywords

Metabolic reprogramming / prostate cancer / castration resistance / endocrine therapies / metabolomics / metabolic imaging / therapy respo nse

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020..CA Cancer J Clin2020;70:7-30

[2] Schrecengost R.Molecular pathogenesis and progression of prostate cancer..Semin Oncol2013;40:244-58 PMCID:PMC3727396

[3] Teo MY,Kantoff P.Treatment of advanced prostate cancer..Annu Rev Med2019;70:479-99 PMCID:PMC6441973

[4] Einstein DJ,Balk SP.Targeting the androgen receptor and overcoming resistance in prostate cancer..Curr Opin Oncol2019;31:175-82 PMCID:PMC6465077

[5] Graf RP,Barnett ES,Dittamore R.Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physician treatment choice in castration-resistant prostate cancer..Eur Urol2020;77:170-7 PMCID:PMC7472426

[6] Salami J,Willard RR.Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance..Commun Biol2018;1:100 PMCID:PMC6123676

[7] Han X,Qin C.Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer..J Med Chem2019;62:941-64

[8] Neklesa T,Willard RR.ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer..J Clin Oncol2019;37:259

[9] Kregel S,Han X.Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment..Neoplasia2020;22:111-9 PMCID:PMC6957805

[10] Lin D,Qu S.Metabolic heterogeneity signature of primary treatment-naïve prostate cancer..Oncotarget2017;8:25928-41 PMCID:PMC5432227

[11] Choi SY,Wu R.The MCT4 Gene: a novel, potential target for therapy of advanced prostate cancer..Clin Cancer Res2016;22:2721-33

[12] Wilson KM.Dehm SM.Diet and lifestyle in prostate cancer..Prostate cancer.2019;ChamSpringer International Publishing1-27

[13] Lin PH,Freedland SJ.An update of research evidence on nutrition and prostate cancer..Urol Oncol2019;37:387-401

[14] Vidal AC,Howard LE.Obesity, race, and long-term prostate cancer outcomes..Cancer2020;126:3733-41

[15] Keto CJ,Terris MK.Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database..BJU Int2012;110:492-8 PMCID:PMC3343219

[16] Barfeld SJ,Urbanucci A.Androgen-regulated metabolism and biosynthesis in prostate cancer..Endocr Relat Cancer2014;21:T57-66

[17] Costello LC.A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer..Arch Biochem Biophys2016;611:100-12 PMCID:PMC5083243

[18] Massie CE,Ramos-Montoya A.The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis..EMBO J2011;30:2719-33 PMCID:PMC3155295

[19] Heemers HV,Swinnen JV.Androgen activation of the sterol regulatory element-binding protein pathway: Current insights..Mol Endocrinol2006;20:2265-77

[20] Chan SC,Li Y.Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies..Nucleic Acids Res2015;43:5880-97 PMCID:PMC4499120

[21] Sharma NL,Ramos-Montoya A.The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man..Cancer Cell2013;23:35-47

[22] Mah C,Swinnen JV.Lipogenic effects of androgen signaling in normal and malignant prostate..Asian J Urol2020;7:258-70 PMCID:PMC7385522

[23] Swinnen JV,Esquenet M,Verhoeven G.Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP..Endocrinology1996;137:4468-74

[24] Swinnen JV,Verhoeven G.Increased lipogenesis in cancer cells: new players, novel targets..Curr Opin Clin Nutr Metab Care2006;9:358-65

[25] Hosios AM.The redox requirements of proliferating mammalian cells..J Biol Chem2018;293:7490-8 PMCID:PMC5961062

[26] Wu X,Wang CJ.FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1..Proc Natl Acad Sci U S A2016;113:E6965-73 PMCID:PMC5111708

[27] Ackerman D.Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment..Trends Cell Biol2014;24:472-8 PMCID:PMC4112153

[28] Swinnen JV,Heyns W.Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins..Proc Natl Acad Sci U S A1997;94:12975-80 PMCID:PMC24248

[29] Swinnen JV,van de Sande T.Androgens, lipogenesis and prostate cancer..J Steroid Biochem Mol Biol2004;92:273-9

[30] Watt MJ,Selth LA.Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer..Sci Transl Med2019;11:eaau5758

[31] Tousignant KD,Taherian Fard A.Lipid uptake is an androgen-enhanced lipid supply pathway associated with prostate cancer disease progression and bone metastasis..Mol Cancer Res2019;17:1166-79

[32] Schlaepfer IR,Rodrigues LU.Lipid catabolism via CPT1 as a therapeutic target for prostate cancer..Mol Cancer Ther2014;13:2361-71 PMCID:PMC4185227

[33] Itkonen HM,Urbanucci A.Lipid degradation promotes prostate cancer cell survival..Oncotarget2017;8:38264-75 PMCID:PMC5503531

[34] Diedrich JD,Herroon MK.Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1alpha activation..Oncotarget2016;7:64854-77 PMCID:PMC5323121

[35] Stoykova GE.Lipid metabolism and endocrine resistance in prostate cancer, and new opportunities for therapy..Int J Mol Sci2019;20:2626 PMCID:PMC6600138

[36] Ettinger SL,Whitmore TG.Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence..Cancer Res2004;64:2212-21

[37] Sharp A,Yuan W.Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer..J Clin Invest2019;129:192-208 PMCID:PMC6307949

[38] Han W,Barrett D.Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer..Oncogene2018;37:710-21 PMCID:PMC5805650

[39] Joshi M,Salzmann-Sullivan M.CPT1A supports castration-resistant prostate cancer in androgen-deprived conditions..Cells2019;8:1115 PMCID:PMC6830347

[40] Zadra G.Metabolic vulnerabilities of prostate cancer: diagnostic and therapeutic opportunities..Cold Spring Harb Perspect Med2018;8:a030569 PMCID:PMC6169980

[41] Li X,Hu P.Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling..Mol Cancer Ther2014;13:855-66 PMCID:PMC4084917

[42] Zadra G,Chetta P.Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer..Proc Natl Acad Sci U S A2019;116:631-40 PMCID:PMC6329966

[43] Kong Y,Mao F.Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)..J Biol Chem2018;293:14328-41 PMCID:PMC6139550

[44] Warburg O.On the origin of cancer cells..Science1956;123:309-14

[45] San-Millan I.Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect..Carcinogenesis2017;38:119-33 PMCID:PMC5862360

[46] Pertega-Gomes N,Massie CE.A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy..J Pathol2015;236:517-30 PMCID:PMC4528232

[47] Lavallee E,Buteau FA.Increased prostate cancer glucose metabolism detected by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration..Eur Urol Focus2019;5:998-1006

[48] Bok R,Sriram R.The role of lactate metabolism in prostate cancer progression and metastases revealed by dual-agent hyperpolarized (13)C MRSI..Cancers (Basel)2019;11:257 PMCID:PMC6406929

[49] Choi SYC,Lin D.Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer..Cancer Med2018;17:3385-92 PMCID:PMC6051138

[50] Zacharias N,Ramachandran S.Androgen receptor signaling in castration-resistant prostate cancer alters hyperpolarized pyruvate to lactate conversion and lactate levels in vivo..Mol Imaging Biol2019;21:86-94 PMCID:PMC6230314

[51] Sreekumar A,Rajendiran TM.Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression..Nature2009;457:910-4 PMCID:PMC2724746

[52] Jentzmik F,Lein M.Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression..J Urol2011;185:706-11

[53] Kaushik AK,Basu S.Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer..J Proteome Res2014;13:1088-100 PMCID:PMC3975657

[54] Shafi AA,Arnold JM.Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells..Oncotarget2015;6:31997-2012 PMCID:PMC4741655

[55] Chi JT,Tolstikov V.Metabolomic effects of androgen deprivation therapy treatment for prostate cancer..Cancer Med2020;9:3691-702 PMCID:PMC7286468

[56] Robinson D,Wu YM.Integrative clinical genomics of advanced prostate cancer..Cell2015;161:1215-28 PMCID:PMC4484602

[57] Zhou X,Sun X.Effect of PTEN loss on metabolic reprogramming in prostate cancer cells..Oncol Lett2019;17:2856-66 PMCID:PMC6386093

[58] Chen M,Sampieri K.An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer..Nat Genet2018;50:206-18 PMCID:PMC6714980

[59] Yang Y,He Y.PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer..Clin Cancer Res2018;24:834-46 PMCID:PMC5816982

[60] Dang CV.MYC, metabolism, cell growth, and tumorigenesis..Cold Spring Harb Perspect Med2013;3:a014217 PMCID:PMC3721271

[61] Dejure FR.MYC and tumor metabolism: chicken and egg..EMBO J2017;36:3409-20 PMCID:PMC5709748

[62] Fleming WH,MacDonald R.Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia..Cancer Res1986;46:1535-8

[63] Hornberg E,Crnalic S.Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival..PLoS One2011;6:e19059 PMCID:PMC3084247

[64] Bernard D,Gil J.Myc confers androgen-independent prostate cancer cell growth..J Clin Invest2003;112:1724-31 PMCID:PMC281646

[65] Bai S,Jin L.A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer..Oncogene2019;38:4977-89 PMCID:PMC6586509

[66] Nadiminty N,Liu C.NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer..Mol Cancer Ther2015;14:1884-95 PMCID:PMC4529751

[67] Barfeld SJ,Persson M.Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer..Oncotarget2015;6:12587-602 PMCID:PMC4494960

[68] Jiang P,Yang X.p53 and regulation of tumor metabolism..J Carcinog2013;12:21 PMCID:PMC3869960

[69] Zawacka-Pankau J,Hunten S.Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer..J Biol Chem2011;286:41600-15 PMCID:PMC3308870

[70] Yahagi N,Matsuzaka T.p53 Activation in adipocytes of obese mice..J Biol Chem2003;278:25395-400

[71] Simabuco FM,Pavan ICB.p53 and metabolism: from mechanism to therapeutics..Oncotarget2018;9:23780-823 PMCID:PMC5955117

[72] Cronauer MV,Burchardt T,Burchardt M.Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines..Oncogene2004;23:3541-9

[73] Maughan BL,Boucher K.p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer..Prostate Cancer Prostatic Dis2018;21:260-8

[74] Castro E,Del Pozo A.PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer..J Clin Oncol2019;37:490-503

[75] Nombela P,Aytes A.BRCA2 and other DDR genes in prostate cancer..Cancers (Basel)2019;11:352 PMCID:PMC6468860

[76] Privat M,Aubel C.BRCA1 induces major energetic metabolism reprogramming in breast cancer cell..PLoS One2014;9:e102438 PMCID:PMC4092140

[77] Zadra G,Loda M.The fat side of prostate cancer..Biochim Biophys Acta2013;1831:1518-32 PMCID:PMC3766375

[78] Patel M,Von Hoff D.Report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640..Cancer Res2015;75:

[79] Brenner AJ,Patel M.Abstract P6-11-09: heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel..Cancer Res2017;77:

[80] Ventura R,Waszczuk J.Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression..EBioMedicine2015;2:808-24 PMCID:PMC4563160

[81] Yang H,Hu X.The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: a systematic review and meta-analysis..J Clin Pharm Ther2020;45:488-95

[82] Shah S,Li J.Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism..Oncotarget2016;7:43713-30 PMCID:PMC5190055

[83] Nassar Z,Machiels J.Lipid elongation in prostate cancer: an androgen regulated process and a novel therapeutic target..Oncol Abstr2019;1:P036

[84] Tamura K,Hullin-Matsuda F.Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism..Cancer Res2009;69:8133-40

[85] Iglesias-Gato D,Tyanova S.The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications..Clin Cancer Res2018;24:5433-44

[86] Flaig TW,Su LJ.Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade..Oncotarget2017;8:56051-65 PMCID:PMC5593544

[87] Xian Z,Chen Q.Inhibition of LDHA suppresses tumor progression in prostate cancer..Tumour Biol2015;36:8093-100 PMCID:PMC4605959

[88] Muramatsu H,Morinaga S.Targeting lactate dehydrogenase-A promotes docetaxel-induced cytotoxicity predominantly in castration-resistant prostate cancer cells..Oncol Rep2019;42:224-30

[89] Xu L,Zeng T.ATM deficiency promotes progression of CRPC by enhancing Warburg effect..Endocr Relat Cancer2019;26:59-71 PMCID:PMC6226046

[90] Bushunow P,Wasenko J.Gossypol treatment of recurrent adult malignant gliomas..J Neurooncol1999;43:79-86

[91] Valencia T,Abu-Baker S.Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis..Cancer Cell2014;26:121-35 PMCID:PMC4101061

[92] Mishra R,Placencio V.Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming..J Clin Invest2018;128:4472-84 PMCID:PMC6159981

[93] Ippolito L,Taddei ML.Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer..Oncogene2019;38:5339-55

[94] Pértega-Gomes N,Vizcaíno JR.A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer..BMC Cancer2014;14:352-60 PMCID:PMC4039335

[95] Vidal AC,Sun SX.Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the shared equal access regional cancer hospital (SEARCH) database..Prostate Cancer Prostatic Dis2017;20:72-8 PMCID:PMC5303130

[96] Peck B.Lipid metabolism at the nexus of diet and tumor microenvironment..Trends Cancer2019;5:693-703

[97] Labbe DP,Yang M.High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program..Nat Commun2019;10:4358 PMCID:PMC6761092

[98] Ngo TH,Anton T.Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence..Cancer Res2004;64:1252-4

[99] Lin PH,Freedland SJ.An update of research evidence on nutrition and prostate cancer..Urol Oncol2019;37:387-401

[100] Freedland SJ,Allen J.A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial..Prostate Cancer Prostatic Dis2019;22:428-37

[101] Freedland SJ,Jarman A.A Randomized controlled trial of a 6-month low-carbohydrate intervention on disease progression in men with recurrent prostate cancer: carbohydrate and prostate study 2 (CAPS2)..Clin Cancer Res2020;26:3035-43

[102] Kelly RS,Giovannucci E.Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence..Cancer Epidemiol Biomarkers Prev2016;25:887-906 PMCID:PMC4891222

[103] Kdadra M,Leung H,Schiffer E.Metabolomics biomarkers of prostate cancer: a systematic review..Diagnostics (Basel)2019;9:21 PMCID:PMC6468767

[104] Huang G,Jiao L.Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer..Eur J Pharmacol2014;729:132-7

[105] Lin HM,Weir JM.A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer..Int J Cancer2017;141:2112-20

[106] Randall EC,Chetta P.Molecular characterization of prostate cancer with associated gleason score using mass spectrometry imaging..Mol Cancer Res2019;17:1155-65 PMCID:PMC6497547

[107] Ren S,Zhao X.Integration of metabolomics and transcriptomics reveals major metabolic pathways and potential biomarker involved in prostate cancer..Mol Cell Proteomics2016;15:154-63 PMCID:PMC4762514

[108] Meller S,Bethan B.Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer..Oncotarget2016;7:1421-38 PMCID:PMC4811470

[109] Alexandrov T.Spatial Metabolomics and Imaging Mass Spectrometry in the Age of Artificial Intelligence..Annu Rev Biomed Data Sci2020;3:61-87

[110] Kurhanewicz J,Carroll P.Multiparametric magnetic resonance imaging in prostate cancer: present and future..Curr Opin Urol2008;18:71-7 PMCID:PMC2804482

[111] Kobus T,Hambrock T.Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T..Radiology2012;265:457-67

[112] Bednarova S,Vinsensia M.Positron emission tomography (PET) in primary prostate cancer staging and risk assessment..Transl Androl Urol2017;6:413-23 PMCID:PMC5503952

[113] Nelson SJ,Vigneron DB.Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate..Sci Transl Med2013;5:198ra08 PMCID:PMC4201045

[114] Chen HY,Bok RA.Hyperpolarized (13)C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study..Prostate Cancer Prostatic Dis2020;23:269-76 PMCID:PMC7196510

[115] Aggarwal R,Kurhanewicz J.Hyperpolarized 1-[(13)C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer..Eur Urol2017;72:1028-9 PMCID:PMC5723206

[116] Dost RJ,Breeuwsma AJ.Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer..Eur J Nucl Med Mol Imaging2013;40:S41-7

[117] Galgano SJ,McConathy J.Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer..Transl Androl Urol2018;7:S462-76 PMCID:PMC6178324